Table 1.
Baseline characteristics of patients in the IMPRESS intervention arm pharmacokinetic study
| Variable | Result (N = 58) |
|---|---|
| Age (years), median (IQR) | 37 (31–42) |
| Male, n (%) | 41 (70.7) |
| Race (black African/Caucasian/coloureda), n (%) | 56 (96.6)/1 (1.7)/1 (1.7) |
| Weight (kg), median (IQR) | 56.9 (51.1–65.2) |
| Fat-free mass (kg) | 46.8 (42.5–50.3) |
| BMI (kg/m2), median (IQR) | 19.6 (18.0–23.3) |
| Alkaline phosphatase (IU/L), median (IQR) | 74.0 (58.0–97.0) |
| Total protein (g/L), median (IQR) | 77.0 (73.0–83.0) |
| Potassium (mmol/L), median (IQR) | 4.5 (4.2–4.9) |
| Bilirubin total (mmol/L), median (IQR) | 6.0 (5.0–9.0) |
| ALT (IU/L), median (IQR) | 18.0 (16.0–30.0) |
| AST (IU/L), median (IQR) | 27.0 (23.0–37.0) |
| Haemoglobin (g/dL), median (IQR) | 11.8 (10.4–12.7) |
| Platelets (109/L), median (IQR) | 407.0 (337.0–477.0) |
| Creatinine clearance (mL/min), median (IQR) | 121.0 (97.0–136.0) |
| HIV status (positive/negative), n (%) | 42 (72.4)/16 (27.6) |
| ART, n (%)b | |
| Efavirenz + emtricitabine + tenofovir | 40 (95.2) |
| Lopinavir/ritonavir + lamivudine + tenofovir | 2 (4.8) |
| CD4+ count (cells/mm3), median (IQR)b,c | 277.0 (139.0–384.0) |
| Viral load (log10 copies/mL)b,d | 3.3 (1.3–4.2) |
a
Mixed race.
b
Only for HIV-positive patients.
c
Four missing data.
d
Five missing data.